Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics Inc (NQ: KRTX )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 Next >
What 9 Analyst Ratings Have To Say About Karuna Therapeutics
Via Benzinga
Karuna Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for KarXT for the Treatment of Schizophrenia
From Karuna Therapeutics, Inc.
Via Business Wire
Analyst Expectations for Karuna Therapeutics's Future
Via Benzinga
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
10 Analysts Have This to Say About Karuna Therapeutics
Via Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
Via Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
Via Benzinga
Where Karuna Therapeutics Stands With Analysts
Via Benzinga
The Latest Analyst Ratings for Karuna Therapeutics
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023
Via Benzinga
Karuna Therapeutics Reports Second Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Leadership Appointments
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics's Return On Capital Employed Overview
Via Benzinga
3 Biotech Buyout Targets to Watch
The trio all have late-stage therapies with blockbuster potential. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2023
Via Benzinga
Karuna Therapeutics to Announce Second Quarter 2023 Financial Results and Provide General Business Update on Thursday, August 3, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Why Shares of Karuna Therapeutics Were Up Wednesday
The clinical-stage biotech announced positive trial results for its lead therapy. 
Via The Motley Fool
What Are Latest Investor Thoughts On Karuna Therapeutics? Analyst Sees Buying Opportunity
William Blair notes increasing investor inbounds on Karuna Therapeutics Inc (NASDAQ: KRTX) given the recent pullback, as the stock is down 13% off June 2023 highs and 25% off 52-week highs  
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Karuna Therapeutics to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the American Society of Clinical Psychopharmacology Annual Meeting
From Karuna Therapeutics, Inc.
Via Business Wire
Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance
Via Benzinga
Karuna Therapeutics Reports First Quarter 2023 Financial Results and Provides General Business Updates
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
PureTech Health FY22 Revenue Declines 10.2% YoY, Here Are The Details
PureTech Health plc (NASDAQ: PRTC) (LSE:PRTC) released its results for the year ended December 31, 2022, revealing revenue of $15.6 million, a decrease of 10.2% compared to $17.4 million in 2021.... 
Via Benzinga
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
From Karuna Therapeutics, Inc.
Via Business Wire
Why Edible Garden Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) shares jumped 69.6% to $15.01 after dropping 24% on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.